RHÖN-KLINIKUM Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Tobias Kaltenbach

İcra Kurulu Başkanı

€507.0k

Toplam tazminat

CEO maaş yüzdesi	98.6%
CEO görev süresi	2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Tobias Kaltenbach'un ücretlendirmesi RHÖN-KLINIKUM'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	€45m
Jun 30 2024	n/a	n/a	€47m
Mar 31 2024	n/a	n/a	€43m
Dec 31 2023	€507k	€500k	€39m
Sep 30 2023	n/a	n/a	€32m
Jun 30 2023	n/a	n/a	€26m
Mar 31 2023	n/a	n/a	€30m
Dec 31 2022	€547k	€83k	€25m

Tazminat ve Piyasa: Tobias 'nin toplam tazminatı ($USD 527.96K ), Swiss pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.35M ).

Tazminat ve Kazançlar: Tobias 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Tobias Kaltenbach (64 yo)

2yrs

Görev süresi

€507,000

Tazminat

Dr. Tobias Kaltenbach is Chief Executive Officer & Chairman of the Management Board at RHÖN-KLINIKUM Aktiengesellschaft from November 2022. Mr. Kaltenbach served as Chairman of Corporate Management at Askl...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tobias Kaltenbach	CEO & Chairman of Management Board	2yrs	€507.00k	Veri yok
Stefan Stranz	CFO & Member of Management Board	4.2yrs	€543.00k	Veri yok
Gunther Weiß	COO & Member of Management Board	6.5yrs	€625.00k	Veri yok
Julian Schmitt	Head of Investor Relations & Treasury	no data	Veri yok	Veri yok
Eugen Münch	Chief Representative	4.3yrs	€219.00k	Veri yok

4.2yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: RHK 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Irmtraut Gurkan	Member of Supervisory Board	4.3yrs	€43.00k	Veri yok
Peter Berghofer	Member of Supervisory Board	14.4yrs	€45.00k	Veri yok
Oliver Salomon	Member of Supervisory Board	6.7yrs	€34.00k	Veri yok
Christine Reißner	Member of Supervisory Board	9.4yrs	€33.00k	Veri yok
Hafid Rifi	Second Deputy Chairman of the Supervisory Board	4.3yrs	€69.00k	Veri yok
Jan Liersch	Chairman of Supervisory Board	4.4yrs	€102.00k	Veri yok
Peter Ducke	Member of Supervisory Board	4.3yrs	€39.00k	Veri yok
Regina Dickey	Member of Supervisory Board	4.3yrs	€45.00k	Veri yok
Thomas Pillukat	Member of Supervisory Board	4.3yrs	€37.00k	Veri yok
Julia Dannath-Schuh	Member of Supervisory Board	4.4yrs	€31.00k	Veri yok
Martin Mandewirth	Member of Supervisory Board	4.3yrs	€35.00k	Veri yok
Stefan Rohrhoff	First Deputy Chairman of the Supervisory Board	less than a year	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: RHK 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

RHÖN-KLINIKUM Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

RHÖN-KLINIKUM Aktiengesellschaft, Annual General Meeting, Jun 09, 2021

RHÖN-KLINIKUM Aktiengesellschaft appoints Christian Höftberger as new CEO

Recent updates

RHÖN-KLINIKUM Aktiengesellschaft to Report Nine Months, 2025 Results on Nov 06, 2025

Second quarter 2024 earnings released: EPS: €0.14 (vs €0.09 in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.16 (vs €0.09 in 1Q 2023)

Full year 2023 earnings released: EPS: €0.58 (vs €0.38 in FY 2022)

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2024 Results on Aug 08, 2024

Third quarter 2023 earnings released: EPS: €0.17 (vs €0.069 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.09 (vs €0.16 in 2Q 2022)

Upcoming dividend of €0.15 per share at 1.2% yield

Full year 2022 earnings released: EPS: €0.38 (vs €0.42 in FY 2021)

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 30, 2023

Second quarter 2022 earnings released: EPS: €0.16 (vs €0.10 in 2Q 2021)

First quarter 2022 earnings released: EPS: €0.01 (vs €0.017 in 1Q 2021)

Third quarter 2021 earnings released: EPS €0.10 (vs €0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.10 (vs €0.003 in 2Q 2020)

First quarter 2021 earnings released: EPS €0.02 (vs €0.066 loss in 1Q 2020)

RHON-KLINIKUM AG Provides Revenue Guidance for the Year 2021

Full year 2020 earnings released: EPS €0.02 (vs €0.65 in FY 2019)

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2021 Results on Aug 05, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day low: CHF26.00

New 90-day low: CHF26.00

New 90-day low: CHF26.00

New 90-day low: CHF26.00

RHÖN-KLINIKUM Aktiengesellschaft, Annual General Meeting, Jun 09, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Q4, 2020 Final Results on Mar 25, 2021

Third quarter 2020 earnings released: EPS €0.09

RHÖN-KLINIKUM Aktiengesellschaft appoints Christian Höftberger as new CEO

New 90-day low: CHF26.00

Medgate Holding AG acquired remaining 51% stake in Medgate Deutschland GmbH from RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK).

RHÃ–N-KLINIKUM Aktiengesellschaft to Report Nine Months, 2020 Results on Nov 06, 2020

Asklepios Kliniken GmbH & Co. KGaA completed the acquisition of additional 42.5% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from HCM SE, B. Braun Melsungen AG, Landeskrankenhilfe V.V.A.G, Asset Management Arm and others for approximately €510 million.

Asklepios Kliniken GmbH concluded the acquisition of additional 12.4% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from Eugen Münch and Ingeborg Münch.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi